Revisiting the Effect of Udenafil on Exercise Performance in Patients With Fontan Circulation: Results of a Post Hoc...

In the FUEL (Fontan Udenafil Exercise Longitudinal) trial, a positive treatment effect was identified for outcomes at the ventilatory anaerobic threshold but not for the primary outcome, oxygen consumption (Vo₂) at peak exercise. This disparate response may be explained by the physiologic challenge of improving peak Vo₂ in participants with near-normal baseline exercise performance.

Participants were divided into subgroups by baseline predicted peak Vo₂ (<80% versus ≥80%). Treatment effect was evaluated in those with a baseline peak Vo₂ <80% predicted and linear regression was performed to examine the interaction between subgroup and response to therapy for the primary and secondary outcomes.

Of the 379 participants with paired exercise data, 302 (80%) had a baseline peak Vo₂ <80% predicted. In this subgroup, the primary outcome of peak Vo₂ improved significantly after 6 months of udenafil treatment, when compared with placebo (0.23±4.17 mL/kg per min versus -0.90±3.74 mL/kg per min; P=0.021). Secondary outcome measures, including Vo₂ at ventilatory anaerobic threshold (P=0.023), work at ventilatory anaerobic threshold (P=0.032), and the myocardial performance index (P=0.007) were all significantly improved as well. A significant interaction was found between exercise subgroups and response to udenafil for peak Vo₂ (P=0.036) but not for other outcomes.

In this post hoc subgroup analysis, after exclusion of patients with Fontan circulation with near-normal baseline peak Vo₂, a positive treatment effect of udenafil was identified for the primary outcome of peak Vo₂. The interaction between baseline peak Vo₂ and treatment may have influenced the outcome of the FUEL trial.

URL: https://clinicaltrials.gov; Unique identifier: NCT0274115.